SpringerLink
Log in

CD226: a potent driver of antitumor immunity that needs to be maintained

  • Research Highlight
  • Published:
Cellular & Molecular Immunology Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Brazil)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Weulersse, M. et al. Eomes-dependent loss of the co-activating receptor CD226 restrains CD8(+) T cell anti-tumor functions and limits the efficacy of cancer immunotherapy. Immunity 53, 824–839. e810 (2020).

    Article  CAS  Google Scholar 

  2. Braun, M. et al. CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8(+) T cells. Immunity 53, 805–823. e815 (2020).

    Article  CAS  Google Scholar 

  3. Martinet, L. & Smyth, M. J. Balancing natural killer cell activation through paired receptors. Nat. Rev. Immunol. 15, 243–254 (2015).

    Article  CAS  Google Scholar 

  4. Johnston, R. J. et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26, 923–937 (2014).

    Article  CAS  Google Scholar 

  5. Zhang, Q. et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat. Immunol. 19, 723–732 (2018).

    Article  CAS  Google Scholar 

  6. Blake, S. J. et al. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov. 6, 446–459 (2016).

    Article  CAS  Google Scholar 

  7. O’Donnell, J. S., Madore, J., Li, X. Y. & Smyth, M. J. Tumor intrinsic and extrinsic immune functions of CD155. Semin. Cancer Biol. 65, 189–196 (2020).

    Article  Google Scholar 

  8. Kucan Brlic, P. et al. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell. Mol. Immunol. 16, 40–52 (2019).

    Article  CAS  Google Scholar 

  9. Li, X. Y. et al. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J. Clin. Investig. 128, 2613–2625 (2018).

    Article  Google Scholar 

  10. Morimoto, K. et al. Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs. Oncogene 27, 264–273 (2008).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Key R&D Program of China (2020YFA0710802) and the Natural Science Foundation of China (reference number 82071768).

Author information

Authors and Affiliations

  1. CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China

    Jiacheng Bi

Authors
  1. Jiacheng Bi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jiacheng Bi.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bi, J. CD226: a potent driver of antitumor immunity that needs to be maintained. Cell Mol Immunol 19, 969–970 (2022). https://doi.org/10.1038/s41423-020-00633-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41423-020-00633-0

  • Springer Nature Limited

Search

Navigation